HealthInvest Partners’s Krystal Biotech KRYS Stock Holding History

HealthInvest Partners’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.93M	Sell	24,019 -13,560	-36%	-$4.05M	2.4%	19
2026 Q1	$6.79M	Buy	37,579 +3,726	+11%	+$991K	2.19%	22
2025 Q4	$8.35M	Sell	33,853 -8,338	-20%	-$1.75M	2.66%	13
2025 Q3	$791K	Buy	42,191 +22,033	+109%	+$3.3M	2.93%	14
2025 Q2	$2.77M	Sell	20,158 -3,333	-14%	-$490K	1.19%	27
2025 Q1	$4.24M	Buy	23,491 +14,289	+155%	+$2.4M	1.87%	19
2024 Q4	$1.47M	Hold	9,202	–	–	0.7%	28
2024 Q3	$1.68M	Buy	9,202 +1,578	+21%	+$304K	0.79%	28
2024 Q2	$1.4M	Buy	7,624 +1,000	+15%	+$168K	0.85%	28
2024 Q1	$1.18M	Hold	6,624	–	–	0.72%	32
2023 Q4	$822K	Buy	+6,624	New	+$735K	0.64%	33
2022 Q4	$11K	Buy	+139	New	+$10.3K	0.02%	38

Other funds holding KRYS

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

MIF

Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

HealthInvest Partners's KRYS Position: Q2 2026 in Review

HealthInvest Partners reduced its Krystal Biotech (KRYS) stake by 36% in Q2 2026, selling an estimated $4.05M and leaving 24,019 shares worth $8.93M. The position accounts for 2.4% of the portfolio, ranked #19.

HealthInvest Partners first reported a position in KRYS in Q4 2022 and has held it in 12 quarters since. 103 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

HealthInvest Partners held 24,019 shares of Krystal Biotech worth $8.93M as of Q2 2026.
HealthInvest Partners sold 13,560 Krystal Biotech shares in Q2 2026, an estimated $4.05M.
Krystal Biotech made up 2.4% of HealthInvest Partners's portfolio in Q2 2026, its #19 holding.
HealthInvest Partners first reported a position in Krystal Biotech in Q4 2022 and has held it in 12 quarters since.
103 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on HealthInvest Partners's 13F filing for Q2 2026, filed 24 Jul 2026.